151 Real-world prognostic value of ePROMs in first-line osimertinib for EGFR-mutant NSCLC: a single-centre cohort

Lung Cancer 2026

View at publisher
Authors: Igor Gomez-Randulfe, Federico Monaca, Catherine Fell, A.S.D.F.M. Parreira, Thitikorn Nuamek, Loredana Mrak, Colin R. Lindsay, Fiona Helen Blackhall, Yvonne Summers, Fábio Gomes, Raffaele Califano, Corinne Faivre Finn
DOI: 10.1016/j.lungcan.2026.109099
Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer survivorship and care Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Lung Cancer
Volume
212
Pages
109099–109099
Publication date
1 February 2026
Language
EN